Eric Zanelli began consulting for Certa Therapeutics in 2025. He contributes to the design and implementation of preclinical and clinical R&D activities.
Eric has 25 years of executive experience in the biotechnology industry. He co-founded Allievex Corp. and was its Head of Research until 2024. He was responsible for all nonclinical and translational medicine aspects of the projects; he was the principal analyst and writer for most of the documents submitted to the FDA. Prior to the founding of Allievex, Eric served as Senior Scientific Advisor at CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), where he focused on the development of lasmiditan for the acute treatment of migraine headaches. He has also served in senior scientific management roles at Peptimmune Inc., Praecis Pharmaceuticals, Inc. and Cardion AG. Additionally, Eric was the Scientific Founder of Décilion Holdings LLC, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He is the co-author of 52 peer-reviewed scientific articles and a co-inventor or sole inventor of 12 families of granted or pending patent applications.
Prior to his industry roles, Eric was a Senior Investigator at the Leiden University Medical Center, Leiden, The Netherlands, from 1996 to 2000 and a Postdoctoral Fellow in the Department of Immunology at the Mayo Clinic, Rochester MN, from 1992 to 1996.
